Postmarketing data on obeticholic acid (Ocaliva) identified a risk for serious liver injury in primary biliary cholangitis (PBC) patients without cirrhosis, the FDA said in a safety communication on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback